摘要:
A low-density parity check (LDPC) decoder comprises a decoded data stream generator that generates a decoded data stream based on a received data stream and a set of matrix-based codewords. The matrix-based codewords form a LDPC parity check matrix H. A decoder control module at least one of prewrites or replaces a selected portion of at least one of the plurality of codewords with zeros prior to generation of the decoded data stream.
摘要:
A decoder memory system comprises a first memory comprising at least a portion of a parity check matrix H. A second memory receives the portion from the first memory and that is associated with a previous decoding iteration. A third memory communicates with the first memory, receives the parity check matrix H and is associated with a current decoding iteration. A fourth memory comprises likelihood ratios. A control module generates a LDPC decoded signal based on the parity check matrix H, the previous decoded iteration and the likelihood ratios.
摘要:
An encoder system includes a receive module that receives a data stream. A parity generation module generates parity bits based on the data stream and a tensor-product code. A parity insertion module combines the parity bits and the data stream to generate encoded bits.
摘要:
A decoder system comprises a tensor-product code (TPC) decoder that decodes a received data stream to generate a decoded signal. A mark module that replaces low-density parity check (LDPC) parity bits of the decoded signal with 0s to generate a reset output signal. A deinterleave module deinterleaves error correction parity bits that are within the reset output signal to generate a deinterleaved signal that comprises a decoded portion and a concatenated portion. The concatenated portion comprises the error correction parity bits. A parity decoder module removes the concatenated portion from the deinterleaved signal.
摘要:
The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
摘要翻译:本发明是由人类NC-37B淋巴母细胞细胞(American Type Culture Collection,Rockville,Md。)生产和合成的称为IL-12或细胞毒性淋巴细胞成熟因子(CLMF)的新型细胞因子蛋白质。 CLMF协同诱导低浓度的IL-2淋巴因子活化杀伤(LAK)细胞的细胞溶解活性,CLMF能够刺激T细胞生长。 还要求的是用于CLMF的克隆基因,其在合适载体中的重组,含有所述载体的转化细胞,由转化细胞产生的重组蛋白和针对CLMF的抗体。
摘要:
The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
摘要翻译:本发明是由人类NC-37B淋巴母细胞细胞(American Type Culture Collection,Rockville,Md。)生产和合成的称为IL-12或细胞毒性淋巴细胞成熟因子(CLMF)的新型细胞因子蛋白质。 CLMF协同诱导低浓度的IL-2淋巴因子活化杀伤(LAK)细胞的细胞溶解活性,CLMF能够刺激T细胞生长。 还要求的是用于CLMF的克隆基因,其在合适载体中的重组,含有所述载体的转化细胞,由转化细胞产生的重组蛋白和针对CLMF的抗体。
摘要:
The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.